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ABSTRACT 
Background: Thrombocytopenia and circulating dysfunctional immune cells are invariably 
observed in patients with cirrhosis. Platelets may form complexes with neutrophils, monocytes and 
T cells modulating their function. We recently reported increased frequencies of platelet-complexed 
neutrophils in cirrhosis with evidence of neutrophil activation upon contact with healthy platelets in 
vitro. Whether this occurs in vivo following platelet transfusion and contributes to systemic 
inflammation and endothelial activation is unknown. 
Aims: To characterise platelet-leucocyte aggregation in cirrhosis and to determine whether elective 
platelet transfusion results in perturbations associated with changes in markers of haemostasis, 
inflammation or endothelial activation. 
Methods: We collected blood from cirrhotics (n=19) before and following elective platelet 
transfusion. We measured platelet-leucocyte aggregation, activation and function and markers of 
platelet activation, systemic inflammation and endothelial activation by flow cytometry. 
Haemostasis was assessed by thromboelastometry and plasma haemostatic proteins.  
Results: We observed a 2.5-fold increase in platelet-complexed neutrophils in patients with 
cirrhosis compared with healthy subjects and 2-fold more platelets attached per monocyte and T 
cell. All platelet-complexed leucocytes expressed higher levels of activation markers and platelet-
complexed neutrophils had higher resting oxidative burst and phagocytic capacity than their non-
platelet-complexed counterparts (p<0.001); most pronounced in patients with cirrhosis. 
Paradoxically, platelet-complexed leucocyte frequency decreased with increasing MELD score. 
Platelet transfusion increased soluble CD40 ligand (platelet activation marker), the frequency of 
platelet-complexed monocytes (p<0.05) and improved haemostatic status.  
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Conclusion: Cirrhotic patients have activated circulating platelet-complexed leucocytes with 
increased platelet-monocyte aggregation following elective platelet transfusion. Elective platelet 
transfusion might therefore exacerbate immune dysfunction in cirrhosis.  
 
Keywords  
Cirrhosis; Portal hypertension; Immunology; Inflammation 
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INTRODUCTION 
Functional alterations in circulating immune cells are well recognised in patients with cirrhosis and 
predict the development of infection, organ dysfunction and thus mortality. The immunological 
disturbance is complex and encompasses both hyper-activation of immune cells, which can cause 
injury and functional immune paralysis impairing the ability to fight infection.1-5 Thrombocytopenia 
is also a well-established feature of cirrhosis with portal hypertension and circulating platelets have 
been reported to be in a pre-activated state.6 Platelets are key in thrombosis and haemostasis, but 
have functions beyond this. Notably, platelets also hold vital immuno-modulatory properties and 
may therefore be involved in the functional leucocyte defects observed in cirrhosis.  
Upon activation, platelets can become attached to leucocytes leading to the formation of platelet 
leucocyte complexes in circulation.7 Platelet-leucocyte aggregation is enhanced by the presence of 
endotoxin and pre-activation of the platelets both of which are observed in cirrhosis. 8, 9 Complex 
formation with platelets enhances oxidative burst and degranulation of neutrophils and monocytes 
and promotes their tissue extravasation.8, 10 The latter is enforced by direct activation of the 
endothelium by activated platelets. 11-14 When platelets interact with lymphocytes, it facilitates their 
entry into lymph nodes.15 Platelets may thus perpetuate the leucocyte priming that is already present 
in cirrhosis.  
There is a paucity of data on platelet-mediated immune-regulation in cirrhosis. In a recently 
published ex vivo study, platelets isolated from patients with cirrhosis had a decreased capability to 
temper neutrophil priming and production of reactive oxygen species (ROS).16 However 
paradoxically, addition of platelets isolated from healthy individuals to cirrhotic neutrophils 
increased the formation of platelet-complexed neutrophils (PCN) and neutrophil adhesion receptor, 
CD11b, expression.16 Such primed neutrophils are suspected to be responsible for end-organ 
damage in sepsis probably owing to augmented systemic inflammation and endothelial activation.16, 
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17 High frequencies of platelet-leucocyte aggregates have been associated with a pro-thrombotic 
state and are thought to be implicated in several cardiovascular diseases 18. This is of particular 
concern as patients with cirrhosis and thrombocytopenia frequently undergo platelet transfusions 
prior to invasive procedures.  
We therefore investigated, firstly, whether there is altered platelet aggregation with neutrophils, 
monocytes and T cells and consequent functional changes in these cells in patients with cirrhosis. 
Secondly, whether a transfusion with healthy platelets given to a patient with cirrhosis electively 
prior to an invasive procedure impacts in anyway on these measures. We hypothesized that platelet-
leucocyte aggregation is augmented in cirrhosis and that this increases leucocyte activation, 
oxidative stress, systemic inflammation and endothelial activation. Furthermore, we hypothesized 
that elective platelet transfusion will exacerbate these events. 
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MATERIALS AND METHODS 
Study design and population 
In this prospective cohort study, we consecutively recruited 19 patients with cirrhosis from King´s 
College Hospital Liver Unit between March and August 2015 scheduled to receive elective platelet 
transfusion prior to invasive procedures. Platelets were transfused prior to procedures when the 
platelet count was below 80x10^9/L according to the local guideline. Blood samples were taken 
prior to administration of platelets and repeated between 1-3 (mean±SD: 1.7±0.8) hours after 
commencing transfusion. We aimed to leave as long as possible from transfusion start to sampling, 
but with sampling occurring before the invasive procedure and before transfusion of additional 
blood products. All post-transfusion blood samples were taken prior to the invasive procedure 
except for one case that was taken after variceal band ligation. Platelet transfusions were in all but 
two cases ABO-matched, and consisted of either pooled platelets or apheresed platelets. Patients 
had between 1 and 2 pools of platelets depending on their platelet count. Blood was taken from 
healthy subjects (n=9) as controls. 
 
Inclusion and exclusion criteria 
Patients with ultrasonic and/or histological verification of cirrhosis of any aetiology, between the 
ages of 18 and 75, and scheduled for elective platelet transfusion were included. Healthy subjects 
with no history of liver and thrombotic disease were included as controls. Findings characteristic of 
cirrhosis on ultrasound included a coarse, nodular heterogeneous parenchyma with or without 
evidence of the development of portal hypertension with splenomegaly, sluggish portal blood flow 
and the development of ascites. Patients were excluded if they had evidence of an acute infection, 
had undergone liver transplantation or had hepatocellular carcinoma outside the Milan criteria.19 
Patients were also excluded if they had received any platelet transfusion in the previous two weeks 
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or had been treated with any anti-platelet therapies, anti-coagulants or immunomodulatory drugs. 
Likewise, none of the healthy subjects recruited had acute infection or had received any of the 
above drugs. Patients were excluded after inclusion if plasma was given before or alongside platelet 
transfusion or if other drugs affecting leucocyte or platelet function were given within the study 
time frame. 
  
Consent and data collection 
The study was granted ethical approval by the North East London Research Ethics Committee [Ref 
08/H0702/52] and was conducted in accordance with the Declaration of Helsinki. Written, informed 
consent was obtained from all study participants prior to study inclusion. Clinical and biochemical 
data were collected and model of end-stage liver disease (MELD) and Child Pugh scores were 
calculated. 
 
Blood sampling 
Venous blood was collected in citrated and EDTA tubes. A tourniquet was used as part of the blood 
collection procedure, but stasis was reduced to the absolute minimum. Samples were transported at 
room temperature and thromboelastometry and flow cytometry assays were performed immediately 
after blood was drawn. Plasma was obtained by centrifugation of whole blood and stored at - 80°C 
for later cytometric bead array analyses and analyses of haemostatic proteins.  
 
Quantification of platelet-complexed leucocytes and leucocyte phenotyping 
A whole blood surface staining was performed with optimized amounts of fluorochrome conjugated 
antibodies; CD41a-PE, CD41a-APC, CD16-PE, CD11b-APC-CY7, CD14-PerCP-Cy5.5, CD4-
APC-H7, CD8-APC, CD25-Pe-CY7, CD69-FITC, CD45RO-PerCP-cy5.5, (Becton Dickinson 
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(BD), UK). Erythrocyte lysis was performed after surface staining with lysis solution (BD, UK) to 
avoid activation of the platelets by erythrocyte lysis. Samples were analysed using a FACS Canto II 
analyser (BD, San Jose, USA). Platelet-leucocyte aggregates were identified by co-expression of 
the platelet marker CD41a (platelet glycoprotein alpha-IIb) with CD16+ granulocytes; PCN, with 
CD14+CD16- (classical monocytes), CD14+CD16+ (intermediate monocytes) and CD14loCD16+ 
(nonclassical monocytes); platelet-complexed monocytes (PCM) and CD4+ or CD8+ T cells; 
platelet-complexed T cells (PCT). Median fluorescence intensity (MFI) of the adhesion receptor 
CD11b was measured on neutrophils and monocytes as a marker of activation and for T cells the 
MFI of the IL-2 receptor, CD25, and CD69 were determined. Unstained samples and fluorescence 
minus ones (FMOs) were included in all flow cytometry experiments as controls. 
 
Leucocyte function tests 
Neutrophil oxidative burst and phagocytosis were measured as previously described and 
degranulation status was measured on both neutrophils and monocytes.20 
Oxidative burst: Oxidative burst was quantified using the PhagoBurst kit (Orpegen Pharma, 
Heidelberg, Germany), which detects rhodamine oxidation as a measure of ROS production in 
unstimulated neutrophils (resting burst) and after stimulation with formyl-Met-Leu-Phe (fMLP) 
(low burst), phorbol 12-myristae 13-acetate (PMA) (high burst) or opsonised E.coli (phagoburst) 
following the manufacturer´s instructions.  
Phagocytic activity and capacity: Phagocytosis was measured with FITC-labelled E.coli using the 
PhagoTest kit (Orpegen Pharma, Heidelberg, Germany) as per manufacturer’s instructions.  
In both assays, cells were stained with CD16-PE and CD41a-APC for 30 minutes in the dark to 
identify PCN. Samples were analysed immediately after preparation. Neutrophil ROS production 
was reported as the percentage of rhodamine positive PCN and as MFI. Neutrophil phagocytosis 
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activity was reported as the percentage of E.coli positive PCN and neutrophil phagocytic capacity 
as the median number of E.coli present within each neutrophil (MFI).  
Degranulation: 
Neutrophil and monocyte degranulation markers were measured both in the extracellular and 
intracellular compartments in unstimulated and E.coli-stimulated cells. One hundred microliters 
whole blood were incubated with 380 μL RMPI and 20 μL PBS or opsonized E.coli at 37°C for 20 
minutes. After washing, half of the tubes were stained with MPO, CD66b, CD11b, CD107a, CD63 
and CD16 (BD, UK) and the other half with CD16 only. Following a 30 minute incubation, the 
cells were washed and lysed and intracellular tubes were permeabilised with 100 μL of 
cytofix/cytoperm solution (BD, UK) and stained with the above-mentioned degranulation markers. 
Expression of the degranulation markers was reported as MFI. 
 
Cytometric bead array 
The markers of platelet activation (sP-selectin and sCD40L), the pro-inflammatory cytokines 
monocyte chemoattractant protein-1 (MCP-1) and the endothelial activation markers (sICAM-1, 
sVCAM-1 and sP-selectin) were quantified using cytometric bead array (BD, UK) from the 
previously stored plasmas. 
 
Thromboelastometry 
Thromboelastometry was performed on citrated whole blood using Rotem® and the assay panel 
included INTEM, EXTEM, FIBTEM and APTEM. INTEM and EXTEM are haemostasis-screening 
tests with activation of the intrinsic (contact phase) or extrinsic (tissue factor) pathways, 
respectively. In FIBTEM, cytochalacsin D was used to inhibit platelets thus isolating the function of 
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fibrin in clot formation, and in APTEM, fibrinolysis was inhibited by aprotinin enabling the 
detection of hyperfibrinolysis. Maximal runtime of the samples was 60 minutes. 
 
Haemostatic assays 
Platelet counts were assessed in whole blood using routine diagnostic methods. In plasma samples, 
markers of primary haemostasis (platelet count, von Willebrand factor (VWF), ADAMTS13), 
coagulation (factor VIII, prothrombin time (PT), international normalized ratio (INR), activated 
partial thromboplastin time (APTT), antithrombin and fibrinogen) and thrombin generation (F1+2, 
thrombin-anti-thrombin complexes (TAT)) were quantified as previously described. 21, 22 Plasma 
fibrinolytic capacity was measured utilising a plasma-based clot lysis time assay, also described 
previously. 21, 22 Plasma thrombin generating potential was measured in vitro in the presence and 
absence of thrombomodulin by calibrated automated thrombography.  
 
Statistics 
Statistical analyses were performed using non-parametric tests. To assess differences between 
groups (cirrhosis patients vs. healthy subjects) we employed Wilcoxon rank-sum test. Wilcoxon 
signed-rank test was used to compare paired data (before and following platelet transfusion) and 
Spearman’s rho for correlation analyses. Results are expressed as median and interquartile range 
(25%; 75%), and a p-value <0.05 was considered statistically significant. 
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RESULTS 
Patient baseline characteristics 
We recruited patients with cirrhosis of any aetiology; alcohol (n=8), cleared hepatitis C virus 
infection (n=5), non-alcoholic fatty liver disease/steatohepatitis (n=2), Wilson’s disease (n=1), 
primary biliary cholangitis (n=1), primary sclerosing cholangitis (n=1), cryptogenic cirrhosis (n=1). 
Patient clinical and biochemical characteristics at inclusion are presented in table 1. Three of the 
patients were actively drinking above the recommended limits and 8 patients were receiving beta-
blockers. These patients did not differ from the rest of the cohort on our outcome measures. Using 
thromboelastometry, we demonstrated significantly impaired haemostasis in this cohort of cirrhosis 
patients compared with controls (table 2). The recruited patients underwent the following 
procedures; variceal banding (n=6), dental procedures (n=4), large volume paracentesis (n=3), 
tracheostomy (n=2), liver biopsy (n=1) and radiofrequency ablation (n=1). One patient was 
excluded from the pre-post comparisons as granulocyte colony stimulating factor (G-CSF) was 
given alongside platelet transfusion and for one patient platelet transfusion was cancelled following 
inclusion. None of the patients experienced haemorrhagic or thrombotic procedure-related 
complications. 
 
Elevated frequencies of PCN and platelet-complexing with monocytes and T cells in cirrhosis 
In patients with cirrhosis, the frequency of PCN was 2.5-fold higher than in healthy subjects (figure 
1A) and a similar tendency was evident in the subset of intermediate monocytes (figure 1B). The 
frequency of platelet-complexes was not different in the other leucocyte subsets investigated (figure 
1C-F). However a greater number of platelets were attached per individual monocyte in the 
population of both classical and intermediate monocytes as well as in T cells in patients with 
cirrhosis (figure 1G). A similar tendency was seen in PCN.  
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Platelet-complexed leucocytes are more activated than non-complexed leucocytes especially in 
cirrhosis  
Neutrophils and monocytes that form complexes with platelets were more activated as measured by 
the expression of CD16 and CD11b than non-complexed neutrophils and monocytes in cirrhosis 
(neutrophil CD16; p=0.0001) (figure 2A). Also for T cells, the expression of CD69 and CD25 was 
higher on platelet-complexed than non-complexed T cells (figure 2B-C). These differences between 
platelet-complexed and non-complexed neutrophils, monocytes and T cells were also found in 
healthy subjects (p<0.05) [data not shown]. However, this difference in expression of activation 
markers between complexed and non-complexed leucocytes was greater in patients with cirrhosis 
than in healthy subjects in both neutrophils (CD16, p=0.0008) and monocytes (figure 2D). The 
same was evident for CD25 expression in CD4+ T cells, but not the case for CD69 or for CD8+ T 
cells (figure 2E). 
 
Increased resting and stimulated burst and phagocytic capacity in PCN  
PCN had a higher resting oxidative burst (p<0.001) than neutrophils not in complex with platelets 
(figure 3A). Additionally, PCN responded with a higher oxidative burst when exposed to fMLP 
than the non-complexed neutrophils (figure 3B). This was not found for the PMA (Fig. 3C) or 
E.coli-induced burst. Similar differences between complexed and non-complexed cells were found 
in healthy subjects [data not shown]. The differences in burst when comparing platelet-complexed 
with non-complexed neutrophils were greatest in patients with cirrhosis for resting burst and fMLP-
stimulated burst and indifferent for PMA (figure 3D-F) and E.coli-induced burst. PCN had a higher 
phagocytic capacity than non-complexed neutrophils in cirrhosis (figure 3G) and in healthy subjects 
(p=0.03), however the difference in phagocytic capacity between complexed and non-complexed 
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neutrophils was equal between the groups (figure 3H). We also investigated neutrophil and 
monocyte degranulation, but found no correlations between PCN or PCM frequency or activation 
and baseline markers of degranulation  [data not shown]. 
 
PCN, PCM, platelet and endothelial activation is reduced in those with advanced cirrhosis 
consistent with immune exhaustion 
Paradoxically, the activation state of PCN was inversely related to MELD score (r=-0.45, p=0.05) 
and similarly for non-classical PCM (r=-0.52, p=0.03) consistent with those with end-stage liver 
disease having evidence of immune exhaustion. The frequency and activation state of platelet 
leucocyte aggregates were not related to platelet count. The platelet activation markers, sCD40L 
and P-selectin, were also inversely related with Child Pugh Score (r=-0.46, p<0.05) and (r=-0.42, 
p=0.076). Furthermore, the endothelial activation marker sVCAM-1 was inversely related with both 
MELD (r=-0.74, p<0.01) and Child Pugh Scores (r=-0.82, p<0.001) [data not shown]. 
 
Changes in platelet leucocyte aggregation induced by platelet transfusion are reflected in 
changes in leucocyte activation 
The frequency of PCN did not significantly differ following platelet transfusion in this cohort of 
cirrhosis patients (figure 1A). When looking at the individual patients, we found that 9 of the 17 
patients responded to transfusion by an increase in PCN and in 8 of the patients the percentage 
decreased. The change in PCN frequency prior, and following platelet transfusion however 
correlated with the change in neutrophil CD11b  (r=0.80, p<0.01) and CD16 (r=0.52, p<0.01) 
expression.  For monocytes, the percentage of PCM increased following platelet transfusion in the 
classical population by 20% and in the non-classical monocytes by 35% (figure 1B, D). Like the 
neutrophils, we observed a positive correlation between the changes in the percentage of PCM and 
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the CD11b expression in the classical monocyte population (r=0.61, p<0.05) and a similar tendency 
in the population of non-classical monocytes (r=0.41, p=0.1). The percentage of platelet-complexed 
T cells did not change following platelet transfusion (figure 1E,F). As for the other leucocytes, 
changes in the percentage of platelet-complexed T cells were reflected in activation changes  [data 
not shown]. 
 
Plasma sCD40L level increase after platelet transfusion 
The plasma level of sCD40L increased following platelet transfusion (p<0.05) but none of the other 
markers of systemic inflammation or endothelial activation changed (figure 4).  
 
Leucocyte function is not affected by platelet transfusion 
We investigated whether platelet transfusion induced functional changes in the leucocytes. 
However, neither neutrophil oxidative burst nor phagocytosis were significantly different following 
platelet transfusion (supplementary table 1) and markers of degranulation expressed on neutrophils 
and monocytes did not change (supplementary table 2). T cell maturation as measured by CD45RO 
was also unchanged. 
 
Platelet transfusion improves haemostatic status 
Table 2 demonstrates an improvement in haemostatic status following platelet transfusion as 
measured by thromboelastometry; time to clot development was reduced (CT), the onset of clot 
formation occurred more rapidly (CFT, Alpha) and a greater clot firmness was obtained (MCF). 
Additionally, clot lysis was decreased (ML). In the FIBTEM assays, where platelets are inhibited by 
cytochalasin-D, these effects were not seen and fibrinolysis was increased. In addition, we 
measured haemostasis parameters in plasma and detected a highly significant decrease in factor 
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VIII and an increase in thrombin-antithrombin complexes following platelet transfusion (Figure 5). 
No clear changes in other haemostatic parameters assessed were observed (supplementary figure 1). 
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DISCUSSION 
In this study, we sought to evaluate the extent of platelet aggregation with neutrophils, monocytes 
and T cells in patients with cirrhosis and observed augmented platelet-complex formation in all 
investigated leucocyte subsets. Platelet aggregation with neutrophils and T cells has to our 
knowledge not previously been investigated in patients with cirrhosis. Studies assessing the 
frequencies of PCM in cirrhosis are conflicting.9, 23, 24 The diverging data may be explained by 
different disease severities investigated and particularly the experimental circumstances; choice of 
anti-coagulant, platelet marker and time to analyses. As platelet leucocyte aggregation is greatly 
affected by these choices, it is vital to treat control and patient samples similarly.25 The studies 
reporting elevated PCM frequencies in cirrhosis detected much lower frequencies of complex 
formation in their healthy control cohorts than we, whilst other reports are in agreement with our 
values.9, 24, 26 A study evaluating platelet aggregation in monocyte subsets detected preferencial 
platelet-complexing with CD16+ monocytes in accordance with our findings.23  
 
Studies support that platelet-complexed leucocytes are a phenotypically and functionally distinct 
compartment of leucocytes that are primed for tissue extravasation and microbial killing.26, 27 
However, this study is the first to show an augmentation of this platelet-induced leucocyte 
activation in cirrhosis. Thrombocytopenia may in itself act as a stimulant as a high platelet-to-
neutrophil ratio has been shown to aid ROS production.28 In addition, ongoing platelet activation in 
cirrhosis may also contribute to augmented platelet-leucocyte complex formation.29, 30 The presence 
of platelet activation in patients with cirrhosis has however been debated as the elevated soluble 
platelet activation markers are cleared by the liver and could solely reflect hepatic dysfunction.31 
The findings which support the presence of platelet activation in cirrhosis are increased platelet 
aggregation, along with increased expression of surface markers measured by flow cytometry, but 
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no consensus has been reached.9 Due to the methodological difficulties in accurately characterising 
the activation status of circulating platelets, assessing the frequencies of PCM has been proposed as 
a sensitive and reliable indicator of platelet activation.32 Based upon our findings and on the 
conflicting reports of PCM frequencies in cirrhosis, we suggest PCN frequency to be a more 
sensitive index of platelet activation in patients with cirrhosis. 
 
In agreement with previous studies, we observed lower frequencies of PCN and PCM with 
increasing disease severity, which was not explained by lowered platelet counts. A similar pattern 
of enhanced complex formation occurs during the systemic pro-inflammatory surge in sepsis and 
with a retraction in platelet leucocyte aggregation as sepsis progresses to septic shock.33 This may 
reflect immune paresis, which frequently follows immune hyper-activation, and which may be 
related to deposition of platelet-leucocyte complexes in the organs as observed in experimental 
models of sepsis.34 
 
We repeated our analyses following an elective platelet transfusion to assess the effects on the 
platelet-leucocyte interplay. We verified utilizing thromboelastometry and plasma-based 
haemostasis tests, that elective transfusion of one or two pools of platelets impacts on haemostatic 
status in these patients. Whether these changes are clinically meaningful however, remains to be 
seen. Plasma levels of sCD40L increased following platelet transfusion, which is indicative of 
platelet activation. However, it has been well established that the handling and storing of platelets 
results in slight platelet activation and increases sCD40L in the transfusate and this can increase 
plasma sCD40L after transfusion.35 Possibly, the cirrhotic platelets also contribute to this plasma 
increase, as sCD40L acts as a cytokine and can activate other platelets.36, 37  
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Consistent with a higher number of circulating platelets following transfusion and their increased 
activation, the frequency of PCM increased. This increase was not evident in neutrophils and T cells 
in our cohort but we observed that some patients responded to platelet transfusion with an increase, 
and others with a decrease, in platelet leucocyte aggregation. These differential responses are likely 
to be a result of the heterogeneity of our cohort, but our limited sample size prevents us from 
identifying the responsible factor.  Nevertheless, the fact that changes in platelet-leucocyte 
aggregation in response to platelet transfusion correlated with increased expression of activation 
markers on neutrophils, monocytes and T cells suggest a potential priming effect of platelet 
transfusion. That platelets stored for transfusion are apt to aggregate with leucocytes and cause their 
activation has previously been demonstrated in vitro.39 We cannot say from this study whether this 
response is unique to cirrhosis patients, but we speculate that this response may at least be more 
pronounced in these patients who at baseline have enhanced activation of their platelet-complexed 
leucocytes. 
 
The pathophysiological consequences of elevated platelet-leucocyte aggregation in patients with 
cirrhosis and its enhancement by platelet transfusion in certain individuals may be of both 
haemostatic and immunological nature. Platelet-leucocyte aggregates are regarded as pro-
thrombogenic, which mechanistically is explained by increased tissue factor production by the 
involved leucocytes accompanied by enhanced fibrin deposition. 40-42 This may add to the already 
increased risk of venous thrombosis in these patients.43 Indeed, the increase in thrombin-
antithrombin complexes following platelet transfusion suggests a prohaemostatic effect of donor 
platelets. Immunologically, further priming of leucocytes within the aggregates augments any pre-
existing cirrhosis-induced hyper-activation and could therefore potentiate systemic inflammation 
and endothelial activation. Indeed, in sepsis-induced multiple organ failure, activated neutrophils 
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have been proposed responsible for inducing or augmenting end-organ injury. 17 Platelet CD40L 
may also, besides any activating effects on leucocytes, act on endothelial cells to produce 
chemokines and up-regulate adhesion receptors that promote tissue extravasation of leucocytes.44 
However, in our study we did not see any changes in systemic inflammation or endothelial 
activation markers after platelet transfusion. Ideally, we would have liked to measure these markers 
as well as leucocyte function at 12 and 24 hours following platelet transfusion but as transfusions 
were performed prior to invasive procedures introducing strong confounding factors such as 
sedatives, stress and mechanical injury, we chose the latest time point before procedure to isolate 
the effects of the transfusion. Prior to initiation of the study, we performed a time course 
experiment on two patients with sampling at one, three and five hours after transfusion, which 
showed that the changes in platelet-complexing had already occurred one hour after transfusion. 
This is in line with a recent publication that demonstrated increased platelet counts one hour after 
elective platelet transfusion in cirrhosis patients.45 However, this may not allow sufficient time for 
possible systemic effects of the complexes to occur.  
 
Although several guidelines still recommend platelet transfusion prior to invasive procedures if 
platelet counts are below 50*109/L suggestions to refrain from this in low risk procedures have been 
raised.46-48 The theoretical background for this is the concept of a “rebalanced haemostasis” in 
cirrhosis, which standard haemostatic tests do not take into account.49 In this study, we observe 
improvement in the haemostatic status as measured by Rotem® after platelet transfusion, which 
could favour the transfusion approach. However, the value of Rotem® as a global haemostasis test 
is questionable as it does not take into account changes in VWF and protein C pathway proteins. A 
recent study demonstrated fewer transfusions with no increase in haemorrhagic incidences when the 
decision basis for elective platelet transfusion in cirrhosis was guided by thromboelastography.50 
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Also, the increases in thrombin-antithrombin complexes with decreases in factor VIII suggest that 
platelet transfusions result in systemic activation of coagulation with potentially harmful effects, 
which may include macrovascular thrombosis and microthrombosis within organs. Furthermore, 
liver disease per se increases the risk for transfusion-related acute lung injury (TRALI), which may 
be explained by platelet-transfusion mediated immune modulation.51 This study raises the potential 
issue of the immune priming effect of platelet transfusion, which varies widely in patients with 
cirrhosis and might lend support to a restrictive approach to platelet transfusion in this setting.  
 
In conclusion, platelet-leucocyte aggregation and the resulting leucocyte activation are enhanced in 
patients with cirrhosis. Elective platelet transfusion may augment these interactions in susceptible 
patients and warrants further investigation.  
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Tables 
Table 1. Baseline patient characteristics. Median (IQR). 
 
  Cirrhosis  
  
 
  
Gender: F/M 6/13   
Age (years) 53 (46;66) 
Aspartate transaminase (10-50 U/L) 48.5 (34;66) 
Bilirubin (0-21μmol/L) 28 (21;85) 
Alkaline phosphatase (35-129 U/L) 144 (94;180) 
Gamma Glutamyl Transferase (5-55 U/L) 72 (27;137) 
Albumin (40-52 g/L) 30 (24;38) 
Sodium (135-145 mmol/L) 137 (132;140) 
Creatinine (45-104 μmol/L) 70 (51;94) 
INR (2.0-3.3) 1.62 (1.25;1.84) 
Hemoglobin (g/L) 109 (98;125) 
Platelets (x10^9/L) 51 (33;61) 
White Blood Cell count (x10^9/L) 3.23 (3.23;2.03) 
Neutrophils (x10^9/L) 2.0 (1.14;3.84) 
Monocytes (x10^9/L) 0.27 (0.17;0.50) 
Lymphocytes (x10^9/L) 0.72 (0.51;1.30) 
MELD Score  16 (10;23) 
Child Pugh score 9 (6;10) 
   (A/B/C)                (5/8/6) 
Temperature (°C) 36.6 (36.3;36.8) 
 
Baseline characteristics of the cirrhosis patients prior to platelet transfusion. INR: international 
normalized ratio. MELD: Model of endstage liver disease. IQR: interquartile range. 
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Table 2. Thromboelastometric improvement in haemostasis following platelet transfusion in 
patients with cirrhosis.  Median (IQR).  
  
 
Healthy 
 
Healthy vs. 
Cirrhosis 
pre plt tx 
Cirrhosis 
Pre plt tx 
Cirrhosis 
Post plt tx 
Cirrhosis 
pre plt tx vs. 
post plt 
tx 
  
median p-value p-value# median (IQR) median (IQR) 
p-value## 
IN CT 201 (178;217) 0.41 205 (196;222) 199.5 (180;218) 0.085 
IN CFT 80 (70;97) 0.0002* 194 (154;247) 174.4 (142;219) 0.03* 
IN Alpha 75 (72;76) 0.0004* 64 (57;70) 66.5 (61;70) 0.0002* 
IN MCF 60 (57;62) 0.0001* 43 (37;49) 47.5 (41;51) 0.002* 
IN A15 57 (54;60) 0.0001* 37 (32;44) 42 (35;46) 0.005* 
IN ML 6 (4.5;11) 0.65 8 (4;12) 6 (4;8) 0.0002* 
EX CT 67 (65;69) 0.31 76 (61;84) 68 (60;76) 0.01* 
EX CFT 93.5 (86.5;113) 0.0002* 187 (150;271) 177.5 (143;212) 0.006* 
EX Alpha 71 (67.5;72.5) 0.01* 63 (55;69) 65 (57;71) 0.0002* 
EX MCF 63 (59.5;65.5) 0.0001* 45 (40;51) 48.5 (43;53) 0.001* 
EX A15 59 (54;60.5) 0.0001* 40 (34;44) 41 (38;47) 0.002* 
EX ML 6.5 (4;11) 0.46 9 (6;13) 7 (4;8) 0.0002* 
AP CT 65 (60;73) 0.59 68 (59;76) 68 (61;77) 0.26 
AP CFT 98 (90;116) 0.0003* 200 (162;251) 173.5 (138;220) 0.004* 
AP Alpha 71 (67;72) 0.12 66 (53;71) 64.5 (56;70) 0.0002* 
AP MCF 62 (60;64) 0.0006* 48 (40;52) 48.5 (44;53) 0.05* 
AP A15 58 (54;59) 0.0002* 40 (34;44) 41 (37;47) 0.009* 
AP ML 5.5 (4;11) 0.51 11 (2;13) 7 (3;03) 0.0002* 
FI CT 67 (60.5;70.5) 0.92 66 (59;79) 65 (60;74) 0.13 
FI MCF 11 (10.5;12) 0.36 12 (10;16) 14.5 (8;17) 0.45 
FI A15 11 (10.5;11,5) 0.63 11 (9;15) 12.5 (8;15) 0.16 
FI ML 2.5 (0.5;4) 0.77 2 (1;7) 3.5 (1;9) 0.01* 
Thromboelastometry was performed on a Rotem® instrument on citrated whole blood in healthy 
subjects and patients with cirrhosis before and at 1-3 hours following an elective platelet transfusion 
and the results compared (#ranksum, ##signrank). Plt tx: platelet transfusion. INTEM: (IN) 
haemostasis activated by contact, EXTEM: (EX) haemostasis activated by tissue factor, APTEM: 
(AP) fibrinolysis inhibited and FIBTEM: (FI) platelets inhibited assays were performed. CT: 
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clotting time, CFT: Clot formation time, alpha: speed of clot formation, MCF: maximum clot 
firmness, A15: clot firmness at 15 minutes, ML: maximum lysis. 
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Figures 
Figure 1 
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Figure 2 
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Figure 3 
 
Figure 4 
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Figure 5 
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Figure legends 
Figure 1. Platelet complexing with leucocytes is augmented in cirrhosis.  
Platelet-complexed neutrophils, monocytes and T cells were quantified by flow cytometry as the 
co-expression of the platelet glycoprotein IIb, CD41a, with leucocyte population markers. (A-F) 
The frequency of these complexes was compared between patients with cirrhosis and healthy 
subjects (ranksum) and patients with cirrhosis before (pre plt tx) and following (post) platelet 
transfusion (signrank). Representative dotplots shown below figures. Unstained samples and 
fluorescence minus ones (FMOs) were included in all flow cytometry experiments as controls. (G) 
Median fluorescence intensity (MFI) of the platelet marker CD41a on the different leucocyte 
populations.(*) p=0.1 *p<0.05 **p<0.01, ***p<0.001. 
 
Figure 2. Platelet-complexed leucocytes are more activated than non-complexed leucocytes 
especially in cirrhosis. 
(A) Expression of the adhesion receptor CD11b was measured by flow cytometry on platelet-
complexed neutrophils and monocytes and compared with the expression on non-platelet-
complexed neutrophils and monocytes. The expression of CD69 (B) and CD25 (C) was similarly 
measured on platelet-complexed CD4+ and CD8+ T cells and compared with non-complexed T 
cells. (D) The difference in CD11b expression between platelet-complexed and non-complexed 
neutrophils and monocytes in cirrhotic patients was compared with healthy subjects. (E) The 
difference in CD25 expression on platelet-complexed and non-complexed T cells was compared 
between the groups. Expression is reported as median fluorescence intensity (MFI). 
Ranksum/signrank, *p<0.05 **p≤0.01, ***p≤0.001. 
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Figure 3. Platelet-complexed neutrophils have higher resting burst, low burst and phagocytic 
capacity than non-complexed neutrophils especially in cirrhosis. 
Citrated whole blood was incubated without stimulation (resting burst) or with formyl-Met-Leu-Phe 
(fMLP) (low burst), phorbol 12-myristae 13-acetate (PMA) (high burst) and the production of 
reactive oxygen species detected by the conversion of dihydro-rhodamine to rhodamine. 
Phagocytosis was measured by incubation with opsonised FITC labelled E.coli bacteria (phagocytic 
capacity). Platelet-complexed neutrophils (PCN) where identified by the expression of CD16 and 
CD41a. Burst/phagocytic capacity is presented as median fluorescence intensity. (A-C) Burst in 
PCN compared with and non-PCN. (D-F) The difference in burst between PCN and non-PCN is 
compared between healthy subjects and patients with cirrhosis. (G) Phagocytic capacity in PCN 
compared with non-PCN. (H) The difference in phagocytic capacity between PCN and non-PCN is 
compared between healthy subjects and patients with cirrhosis. Ranksum and signrank, ns: not 
significant, *p<0.05, ***p<0.001. 
 
 
Figure 4. Plasma soluble CD40 ligand (sCD40L) is increased after platelet transfusion in 
patients with cirrhosis. 
We employed a cytometric bead array to measure sCD40L in EDTA plasma. Levels were compared 
before and following platelet transfusion (plt tx) in patients with cirrhosis.  Signrank, median, 
interquartile range, **p<0.01. 
 
Figure 5.  Platelet transfusion decreases factor VIII and increases thrombin-antithrombin 
complexes. The plasma levels of (A) factor VIII and (B) thrombin-antithrombin complexes were 
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measured in plasma before and following an elective platelet transfusion (plt tx) in patients with 
cirrhosis and the levels compared (signrank). 
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Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet 
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Supplementary table 1. Neutrophil oxidative burst and phagocytosis is increased in cirrhosis 
but not altered by platelet transfusion  
  Healthy Cirrhosis 
      Pre plt tx   Post plt tx   
  Median (IQR) Median (IQR) p-value Median (IQR) p-value 
Resting burst (%) 0.59 (0.42;0.84) 1.76 (1.02;3.74) 0.002* 1.5 (1.25;3.23) 0.66 
Resting burst (MFI) 65.5 (41.12;75.5) 95.5 (87;191) 0.08 132 (83.5;208) 0.38 
Low Burst (%) 37 (23.3;39.0) 46.6 (32.4;72.0) 0.06 53 (43.5;77.3) 0.91 
Low Burst (MFI) 253.4 (142.9;395) 1180 (540;1758) 0.01* 1127 (667.7;2320) 0.5 
High Burst (MFI) 56019 (37908;71638) 119464 (57458;149053) 0.09 107904 (79701;140386) 0.96 
PhagoBurst (MFI) 29567 (23022;32280) 91720 (63328;151653) 0.001* 93821 (80412;134667) 0.95 
Phagocytic potential (%) 76.4 (70.3;85.0) 92.4 (85;97) 0.18 91.1 (87.4;94.5) 0.79 
Phagotic capasity (MFI 6239 (3924;10469) 7360 (4875;16375) 0.82 7041 (5673;12560) 0.83 
                  
 
Neutrophil oxidative burst was measured in whole blood by flow cytometry as the conversion of 
dihydrorhodamine to rhodamine. The neutrophils were unstimulated (resting burst) or stimulated 
with formyl-Met-Leu-Phe (fMLP) (low burst), phorbol 12-myristae 13-acetate (PMA) (high burst) 
or opsonised E.coli (phagoburst). The percentage of rhodamine positive cells and the median 
fluorescence intensity (MFI) of rhodamine were compared between patients with cirrhosis and 
healthy subjects (ranksum) and in patients with cirrhosis before and following a platelet transfusion 
(signrank). Phagocytosis was measured as the ability of neutrophils to take up opsonized FITC 
labelled E.coli and similar comparisons were performed. 
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Supplementary table 2. Neutrophil and monocyte expression of degranulation markers are 
not altered by elective platelet transfusion in patients with cirrhosis  
A  
 Neutrophils 
  
Healthy 
Cirrhosis 
Pre plt tx   Post plt tx   
  Median (IQR) Median (IQR) p-value Median (IQR) p-value 
Unstim EC                 
CD63 140 (75;176) 127 (83;175) 0.57 123 (73;169) 0.55 
CD107a 37 (8;235) 101 (23;144) 0.77 55 (17;132) 0.28 
CD66b 340 (231:592) 840 (501;1210) 0.12 732 (365;1030) 0.69 
Unstim IC                 
CD63 10597 (7458;12190) 12368 (7749;14258) 0.4 13002 (11430;15626) 0.88 
MPO 741 (614;1470) 1650 (1067;2380) 0.01* 1975 (1208;2646) 0.68 
CD107a 102 (1;156) 400 (180;626) 0.003* 287 (106;630) 0.51 
CD66b 3084 (2803;4158) 6815 (4947;10783) 0.002* 7163 (5306;12242) 0.36 
E.coli EC                 
CD63 3161 (2630;3924) 2966 (2302;3396) 0.52 2820 (2220;3620) 0.14 
MPO 48 (36;80) 173 (84;230) 0.02* 114 (73;172) 0.82 
CD107a 60 (-84;511) 494 (127;728) 0.07 444 (166;777) 0.88 
CD66b 3921 (3075;4688) 7406 (4733;9131) 0.01* 6703 (4971;7752) 0.47 
Ecoli IC                 
CD63 6011 (5267;8306) 7527 (5704;11888) 0.2 6614 (5716;9098) 0.14 
MPO 822 (576;1277) 1714 (927;2305) 0.01* 1424 (850;1955) 0.51 
CD107a -40 (-107;60) 367 (35;651) 0.006* 121 (-42;859) 0.43 
CD66b 6982 (5950;7632) 12370 (8922;17733) 0.003* 11424 (7326;17005) 0.64 
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B 
 Monocytes 
  
 
Healthy 
Cirrhosis 
Pre plt tx   Post plt tx   
  Median (IQR) Median (IQR) p-value# Median (IQR) p-value## 
Unstim EC                 
CD63 776 (634;872) 581 (263;951) 0.54 609 (485;1025) 0.26 
MPO 1.3 (1.3;2.6) 2.6 (-2.6;9) 0.75 3.9 (0;11.6) 0.30 
CD107a 25.7 (11.5;96.4) 73 (45;202) 0.09 166 (73;205) 0.33 
CD66b 0 (-3.8;3.9) 11.6 (2.0;27.2) 0.04* 7.7 (1.3;11.6) 0.82 
Unstim IC                 
CD63 1927 (763;2077) 4356 (2311;6284) 0.002* 3426 (3081;4419) 0.056 
MPO 115 (75;145) 387 (282;559) 0.0009* 316 (233;370) 0.16 
CD107a 221 (158;423) 782 (570;1069) 0.0008* 1019 (511;1704) 0.68 
CD66b 44 (19;63) 158 (100;240) 0.002* 131 (79;247) 0.20 
E.coli EC                 
CD63 1698 (1005;2909) 2037 (116;4205) 0.6 2932 (147;3975) 0.73 
MPO 35 (20;90) 59 (9;173) 0.5 96 (-10;152) 0.83 
CD107a -7.1 (-16.7;52.1) 200 (33;404) 0.004* 237 (54;283) 0.93 
CD66b 15 (8;27) 65 (18;108) 0.03* 64 (2.5;107) 0.71 
E.coli IC                 
CD63 2826 (2268;4029) 6122 (4007;7027) 0.002* 5161 (3862;7430) 0.16 
MPO 405 (286;488) 680 (302;1122) 0.1 728 /474;904) 0.55 
CD107a 667 (549;852) 1913 (832;2615) 0.01* 1548 (883;2605) 0.64 
CD66b 90 (64;98) 230 (112;279) 0.005* 177 (131;227) 0.25 
                  
 
Citrated whole blood was incubated with PBS (unstimulated) or opsonised E.coli. Subsequently, 
cells were stained for a panel of degranulation markers either extracellularly [EC] or following 
permeabilisation, intracellularly [IC]. The expression was measured on neutrophils and monocytes 
by flow cytometry and reported as median fluorescence intensity. Expression in patients with 
cirrhosis was compared with expression in healthy subjects (# ranksum) and expression before (Pre) 
and following (Post) platelet transfusion (plt tx) was also compared (##signrank). 
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Supplementary figure 1. Thrombin-generation potential is not altered by platelet transfusion 
in patients with cirrhosis. 
 
 
Thrombin-generation was measured in the absence (A-D) and presence (E-H) of thrombomodulin 
in plasma from patients with cirrhosis before and following an elective platelet transfusion and the 
levels compared (signrank). 
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